Meeting
2019 Gastrointestinal Cancers Symposium
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
Authors
Josep Tabernero
Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain
Josep Tabernero , Alberto F. Sobrero , Christophe Borg , Atsushi Ohtsu , Robert J. Mayer , Loïck Vidot , Shanti Ricardo Moreno Vera , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01607957
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 677)
DOI
10.1200/JCO.2019.37.4_suppl.677
Abstract #
677
Poster Bd #
N2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC).
First Author: Hideaki Bando
Poster
2020 Gastrointestinal Cancers Symposium
Exploratory analysis of trifluridine/tipiracil in late-stage metastatic colorectal cancer (mCRC): Prognostic factors.
First Author: Meinolf Karthaus
Poster
2020 Gastrointestinal Cancers Symposium
Identification of the optimal patients for trifluridine/tipiracil (FTD/TPI) treatment in mCRC: A Spanish real-world analysis.
First Author: Ana Fernandez Fernandez Montes
Poster
2022 ASCO Annual Meeting
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
First Author: Joris van de Haar